The medical center will use the two-year grant to evaluate donor and recipient apolipoprotein L1, proteins that bind lipids, and their renal-risk variants to determine their effect on transplant outcomes.
The grant will also establish a collaborative network called the APOL1 Long-term Transplantation Outcomes Network.
“Findings from [this] study have the potential to alter clinical practice by increasing the numbers of kidneys available for transplantation and improving matching of kidneys with recipients to extend post-transplant kidney function,” said Barry Freedman, MD, nephrologists at Wake Forest Baptist Medical Center.
More articles on healthcare finance:
Swedish Health’s Cherry Hill campus no longer at risk of losing Medicare funding
Missouri hospital’s Medicare contract no longer at risk
OIG: Replacement of 7 recalled and prematurely failed medical devices cost Medicare $1.5B over a decade
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.